Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL7041116 | 0.98 | HDAC3 (0.37) | HDAC3PARP1HSD17B3CA1CA2 | |
| Hydrochloric Acid SCHEMBL23501064 | 0.98 | PARP1 (0.39) | HDAC3PARP1HSD17B3CA1CA2 | |
| Hydrochloric Acid SCHEMBL4419624 | 0.98 | PARP1 (0.39) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL3069885 | 0.77 | HDAC3 (0.43) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL4854749 | 0.74 | HDAC3 (0.41) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL13932579 | 0.74 | HDAC3 (0.38) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL29612167 | 0.74 | HDAC3 (0.41) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL143063 | 0.74 | HDAC3 (0.38) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL1564351 | 0.74 | HDAC3 (0.41) | HDAC3PARP1HSD17B3CA1CA2 | |
| SCHEMBL11353696 | 0.74 | HDAC3 (0.38) | HDAC3PARP1HSD17B3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116355614-A | Etching composition | 安集微电子科技（上海）股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-115210339-A | Etching solution for titanium nitride and molybdenum conductive metal wires | 弗萨姆材料美国有限责任公司 | 2022-10-18 | — | — | CN | claimed |
| CN-108925135-A | Synthetic method for preparing (S) - (2R,3R,11bR) -3-isobutyl-9, 10-dimethoxy-2, 3,4,6,7,11 b-hexahydro-1H-pyrido [2,1-a ] isoquinolin-2-yl-2-amino-3-methylbutyrate bis (4-methylbenzenesulfonate) | 纽罗克里生物科学有限公司 | 2018-11-30 | — | — | CN | claimed |
| CN-107921032-A | Inhibitors of VMAT2 for use in treating neurological diseases or disorders | 纽罗克里生物科学有限公司 | 2018-04-17 | — | — | CN | claimed |
| EP-1638970-A1 | PYRID (2, 1-A) - ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | claimed |
| EP-1638968-A1 | HEXAHYDROPYRIDOISOQINOLINES AS DPP-IV INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000846-A1 | HEXAHYDROPYRIDOISOQINOLINES AS DPP-IV INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| WO-2005000848-A1 | PYRIDO` 2, 1-A - ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| EP-1461337-A1 | PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-29 | — | — | EP | claimed |
| WO-2003055881-A1 | PYRIDO(2,1-A)ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-10 | — | — | WO | claimed |
| CN-1035057-C | Method of preventing polymer scale formation | SHINETSU CHEMICAL CO (JP) | 1997-06-04 | — | — | CN | claimed |
| EP-0355575-B1 | Method of preventing polymer scale formation | SHINETSU CHEMICAL CO (JP) | 1994-11-02 | — | — | EP | claimed |
| EP-0324184-B1 | 2-Amino-1,2,3,4-tetrahydroisoquinoline derivatives, method for their preparation and their use as medicines | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1994-09-28 | — | — | EP | claimed |
| US-5298220-A | Forming a coating of a solution containing anioic and cationic dyes and water insoluble organonitrogen compound, drying | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1994-03-29 | — | — | US | claimed |
| US-5196164-A | During addition polymerization, wall coating of anionic dye and cationic dye and organonitrogen compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1993-03-23 | — | — | US | claimed |
| CN-1040206-A | Prevent to form the method for polymer scale formation | SHINETSU CHEMICAL CO (JP) | 1990-03-07 | — | — | CN | claimed |
| EP-0324184-A2 | 2-Amino-1,2,3,4-tetrahydroisoquinoline derivatives, method for their preparation and their use as medicines | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1989-07-19 | — | — | EP | claimed |
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-0355575-A2 | Method of preventing polymer scale formation | Shin-Etsu Chemical Co., Ltd. (JP) | 1990-02-28 | — | — | EP | disclosed |
| US-3846412-A | DIHYDRO-2-AMINO-ISOQUINOLINES AND THEIR DERIVATIVES | LEPETIT SPA | 1974-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, EGFR, WEE2 | HDAC3 4579/4885PARP1 3221/4885HSD17B3 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.